Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 184HER2-positive Breast Cancer 18Neoplasms 13Neoplasm Metastasis 11Prostatic Neoplasms 7Ovarian Neoplasms 7Stomach Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Inflammatory Breast Neoplasms 5Colonic Neoplasms 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Multiple Myeloma 4Hematologic Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Solid Tumor 3Rectal Neoplasms 3Pathologic Complete Response 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3HER2-positive Early Breast Cancer 3Esophageal Neoplasms 3Breast Neoplasms, Male 3Biliary Tract Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Salivary Gland Neoplasms 2Locally Advanced Breast Cancer 2

Interventions

Surveys and Questionnaires 3vandetanib 1pertuzumab 1gallium Ga 68 dotatate 1fluorodopa F 18 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Leflunomide 1Lansoprazole 1Immunotherapy 1Erlotinib Hydrochloride 1Drug Therapy 1Biological Therapy 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Endocrine Neoplasia × pertuzumab × Clear all
NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡